The Stromal and Immune Landscape of Colorectal Cancer Progression during Anti-EGFR Therapy

Publication date: 8 July 2019Source: Cancer Cell, Volume 36, Issue 1Author(s): Irene Catalano, Livio TrusolinoIn this issue of Cancer Cell, Woolston et al. show that colorectal cancers that become refractory to initially effective anti-EGFR therapy contain an abundance of stromal and immune cells, irrespective of the contextual presence of resistance-conferring mutations. This reconfiguration puts forward therapeutic opportunities for patients who relapse on EGFR-targeting treatment.
Source: Cancer Cell - Category: Cancer & Oncology Source Type: research